Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -1.37% | 203.17 | 1.3% | $753.07m | |
| GILD | Gilead Sciences, Inc. | 0.05% | 63.47 | 0.9% | $381.71m | |
| CELG | Celgene Corporation | 0.04% | 95.26 | 1.3% | $343.41m | |
| BIIB | Biogen Inc. | -1.88% | 231.28 | 1.3% | $298.49m | |
| ILMN | Illumina, Inc. | -1.39% | 284.65 | 3.5% | $294.02m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.80% | 183.72 | 1.9% | $258.56m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.11% | 111.43 | 2.0% | $246.10m | |
| EXAS | Exact Sciences Corporation | 1.10% | 119.46 | 24.1% | $244.15m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.79% | 296.03 | 2.6% | $213.21m | |
| A | Agilent Technologies, Inc. | -0.86% | 71.13 | 1.6% | $201.92m | |
| SRPT | Sarepta Therapeutics, Inc. | -15.16% | 102.07 | 14.7% | $172.24m | |
| INCY | Incyte Corporation | -0.50% | 84.10 | 2.5% | $98.20m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.16% | 76.51 | 4.3% | $93.30m | |
| GHDX | Genomic Health, Inc. | -0.49% | 73.86 | 1.8% | $87.01m | |
| SGEN | Seattle Genetics, Inc. | -0.96% | 78.63 | 6.5% | $81.93m |
Company Profile
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.